The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place from September 13 to ...

For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

Oncologists are perturbed by the increase in early-onset tumors and the potential role of lifestyle, though this may not ...

For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, ...

Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

Results were presented today at the European Society for Medical Oncology (ESMO) Congress in an oral presentation t Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We ...

Results were presented today at the European Society for Medical Oncology (ESMO) Congress in an oral presentation t Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We ...

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...

Metformin does not improve survival in unselected patients with metastatic hormone-sensitive prostate cancer (mHSPC), but the drug may improve survival and other outcomes in those with high-volume ...